Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rudin

Showing results (281-290 of 524) with videos related to

Pageof 53
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2022
Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancerJoshua A Korsen, Julia A Gutierrez, Kathryn M Tully, et al.
Science Signaling|February 7, 2019
Targeting NOTCH activation in small cell lung cancer through LSD1 inhibitionArnaud Augert, Emily Eastwood, Ali H Ibrahim, et al.
Cancer Biology & Therapy|July 14, 2011
Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenograftsYu-An Zhang, Anirban Maitra, Jer-Tsong Hsieh, et al.
Cancer Cell|January 8, 2013
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonistsJames Kim, Blake T Aftab, Jean Y Tang, et al.
NPJ Precision Oncology|July 16, 2024
Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapyArielle Elkrief, Eder Orlando Méndez-Salazar, Jade Maillou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 4, 2007
A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancerChristopher G Azzoli, Lee M Krug, Vincent A Miller, et al.
Cancer Research|July 11, 2025
RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung AdenocarcinomaAlessandro M Mozzarelli, Antonio Cuevas-Navarro, Emily G Shuldiner, et al.
Lung Cancer (Amsterdam, Netherlands)|May 31, 2011
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancerPaul K Paik, Charles M Rudin, Maria C Pietanza, et al.
Biorxiv : the Preprint Server for Biology|October 14, 2020
TMEM41B is a pan-flavivirus host factorH-Heinrich Hoffmann, William M Schneider, Kathryn Rozen-Gagnon, et al.
Cell|December 18, 2020
TMEM41B Is a Pan-flavivirus Host FactorH-Heinrich Hoffmann, William M Schneider, Kathryn Rozen-Gagnon, et al.
Pageof 53

Showing results (281-290 of 524) with videos related to

Sort By:
Pageof 53
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2022
Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancerJoshua A Korsen, Julia A Gutierrez, Kathryn M Tully, et al.
Science Signaling|February 7, 2019
Targeting NOTCH activation in small cell lung cancer through LSD1 inhibitionArnaud Augert, Emily Eastwood, Ali H Ibrahim, et al.
Cancer Biology & Therapy|July 14, 2011
Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenograftsYu-An Zhang, Anirban Maitra, Jer-Tsong Hsieh, et al.
Cancer Cell|January 8, 2013
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonistsJames Kim, Blake T Aftab, Jean Y Tang, et al.
NPJ Precision Oncology|July 16, 2024
Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapyArielle Elkrief, Eder Orlando Méndez-Salazar, Jade Maillou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 4, 2007
A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancerChristopher G Azzoli, Lee M Krug, Vincent A Miller, et al.
Cancer Research|July 11, 2025
RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung AdenocarcinomaAlessandro M Mozzarelli, Antonio Cuevas-Navarro, Emily G Shuldiner, et al.
Lung Cancer (Amsterdam, Netherlands)|May 31, 2011
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancerPaul K Paik, Charles M Rudin, Maria C Pietanza, et al.
Biorxiv : the Preprint Server for Biology|October 14, 2020
TMEM41B is a pan-flavivirus host factorH-Heinrich Hoffmann, William M Schneider, Kathryn Rozen-Gagnon, et al.
Cell|December 18, 2020
TMEM41B Is a Pan-flavivirus Host FactorH-Heinrich Hoffmann, William M Schneider, Kathryn Rozen-Gagnon, et al.
Pageof 53